Maria Pia Sormani

Department of Health Sciences (DISSAL)

Italy

Institute of Hospitalization and Care with a Scientific Character (IRCCS) - Ospedale Policlinico San Martino

Genoa

Italy

SCHOLARLY PAPERS

2

DOWNLOADS
Rank 29,237

SSRN RANKINGS

Top 29,237

in Total Papers Downloads

1,971

SSRN CITATIONS

0

CROSSREF CITATIONS

1

Scholarly Papers (2)

1.

Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis

Number of pages: 32 Posted: 08 Jul 2020
Department of Health Sciences (DISSAL), Centro Sclerosi Multipla ASST Spedali Civili di Brescia, Department of Health Sciences, University of Genova, Department of Health Sciences, University of Genova, Centro Sclerosi Multipla ASST Spedali Civili di Brescia, Department of Neurology, Multiple Sclerosis Center, IRCCS Ospedale San Raffaele, Department of Neurology and Multiple Sclerosis Center, ASST “Papa Giovanni XXIII, Multiple Sclerosis Center, Ospedale Guglielmo da Saliceto, Regional Referral Multiple Sclerosis Centre, Dept. of Neurology, University Hospital San Luigi, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Research Department, Italian Multiple Sclerosis Foundation, University of Campania “Luigi Vanvitelli” - First Division of Neurology, Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, Research Department, Italian Multiple Sclerosis Foundation, Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, University of Rome I - Department of Neuroscience, Mental Health and Sensory Organs and affiliation not provided to SSRN
Downloads 1,931 (9,694)
Citation 12

Abstract:

Loading...

Multiple Sclerosis; coronavirus; Immunomodulatory therapies; Immunosuppressive therapies

2.

Efficacy and Safety of Temelimab, an Antibody Antagonist of the Human Endogenous Retrovirus Type-W env Protein, in Participants with Relapsing Remitting Multiple Sclerosis: A Double-Blind, Randomised, Placebo-Controlled Phase 2b Clinical Trial

Number of pages: 130 Posted: 17 May 2019
Heinrich Heine University Dusseldorf - Department of Neurology, University of Basel - University Hospital Basel, University of California, San Francisco (UCSF) - Weill Institute for Neurosciences, Department of Health Sciences (DISSAL), Medical University of Lodz, University College London - Institute of Neurology, University College London - Institute of Neurology, University College London - Institute of Neurology, Servier International Research Institute (IRIS), GeNeuro SA, GeNeuro SA, Servier International Research Institute (IRIS), GeNeuro SA, GeNeuro SA and VU University Amsterdam - Neuroscience Campus Amsterdam
Downloads 40 (502,689)

Abstract:

Loading...

Multiple sclerosis; HERV-directed temelimab; phase 2 trial; neuroprotection